Progression of liver disease and associated risk of hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) is the primary liver cancer type, often seen in individuals with chronic liver disease. Once the patient progresses to the cirrhotic stage, the annual incidence of HCC is approximately 2%-4%. As it exceeds the minimum threshold of 1.0%-1.5% per year, HCC screening every 6 months through abdominal ultrasound is indicated in the cirrhotic population. While the incidence of viral hepatitis-associated HCC is decreasing, there is a notable rise of HCC associated with metabolic dysfunction-related steatotic liver disease and alcohol-related liver disease, particularly in high-income countries. The most effective approach for oncological prevention remains addressing the cause of liver disease. The indications for HCC screening in patients without cirrhosis depend on the etiology of liver disease and the stage of fibrosis, assessed by liver biopsy or noninvasive tests such as FIB-4 or transient elastography. However, clear recommendations for HCC screening in patients without cirrhosis and for the different etiologies are currently unavailable. Research efforts should focus on identifying markers, or combinations thereof, to provide a more accurate estimate of HCC occurrence. Such advancements would enable the effective targeting of populations at the highest risk of HCC and the establishment of the correct timing to start the screening.

Keywords

HCC / chronic liver disease / cirrhosis / HCC screening

References

[1] Rumgay H,Ferlay J.Global burden of primary liver cancer in 2020 and predictions to 2040.J Hepatol2022;77:1598-606

[2] Overall indications and results for liver transplantation in Europe. Available online: http://www.eltr.org/spip.php?article161[Last accessed on 28 Mar 2022]

[3] Nevola R,Rosato V.Gender differences in the pathogenesis and risk factors of hepatocellular carcinoma.Biology2023;12:984 PMCID:PMC10376683

[4] Vij M.Pathologic and molecular features of hepatocellular carcinoma: an update.World J Hepatol2021;13:393-410 PMCID:PMC8080551

[5] Zhuravleva E,Andersen JB.Mutational signatures and processes in hepatobiliary cancers.Nat Rev Gastroenterol Hepatol2022;19:367-82

[6] Fernández-Barrena MG,Colyn L,Avila MA.Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg.JHEP Rep2020;2:100167 PMCID:PMC7585149

[7] Llovet JM,Kelley RK.Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.Nat Cancer2022;3:386-401 PMCID:PMC9060366

[8] Nenu I,Topor I.Interleukin-6 in hepatocellular carcinoma: a dualistic point of view.Biomedicines2023;11:2623 PMCID:PMC10603956

[9] Allaire M,Thabut D.Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses….Liver Int2021;41:1734-43

[10] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[11] Sagnelli E,Russo A,Sagnelli C.Epidemiological and etiological variations in hepatocellular carcinoma.Infection2020;48:7-17

[12] Devarbhavi H,Arab JP,Pose E.Global burden of liver disease: 2023 update.J Hepatol2023;79:516-37

[13] Liu Y,Hao J.Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019.Cancer Med2022;11:1310-23 PMCID:PMC8894698

[14] Parikh ND,Hutton DW.Cost-effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms.Am J Gastroenterol2020;115:1642-9 PMCID:PMC7541544

[15] Singal AG,Llovet JM.Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy.Nat Rev Clin Oncol2023;20:864-84

[16] Tzartzeva K,Rich NE.Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis.Gastroenterology2018;154:1706-18.e1 PMCID:PMC5927818

[17] Pinto Marques H,De Martin E,Martins PN.Emerging biomarkers in HCC patients: current status.Int J Surg2020;82S:70-6

[18] Parikh ND,Singal AG.Blood-based biomarkers for hepatocellular carcinoma screening: approaching the end of the ultrasound era?.J Hepatol2023;78:207-16 PMCID:PMC10229257

[19] Shen C,Li M.Hepatitis virus and hepatocellular carcinoma: recent advances.Cancers2023;15:533 PMCID:PMC9856776

[20] Péneau C,La Bella T.Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma.Gut2022;71:616-26 PMCID:PMC8862055

[21] Dhanasekaran R,Roberts LR.Genomic medicine and implications for hepatocellular carcinoma prevention and therapy.Gastroenterology2019;156:492-509 PMCID:PMC6340723

[22] Ligat G,Baumert TF.Hepatitis B virus core variants, liver fibrosis, and hepatocellular carcinoma.Hepatology2019;69:5-8 PMCID:PMC6324981

[23] Battistella S,Gambato M.Hepatocellular carcinoma risk in patients with HBV-related liver disease receiving antiviral therapy.Minerva Gastroenterol2021;67:38-49

[24] Kim JH,Kang W.Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment.Hepatology2017;66:335-43

[25] Jang TY,Liu TW.Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues.Sci Rep2021;11:8184 PMCID:PMC8047028

[26] Kamal H,Simin J.Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: a systematic review and meta-analysis of longitudinal studies.J Viral Hepat2021;28:1431-42

[27] Hao X,Zeng HM.Hepatocellular Carcinoma risk scores from modeling to real clinical practice in areas highly endemic for hepatitis B infection.J Clin Transl Hepatol2023;11:1508-19 PMCID:PMC10752803

[28] Paik N,Lee JH.Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia.Liver Int2018;38:68-75

[29] Papatheodoridis G,Sypsa V.PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.J Hepatol2016;64:800-6

[30] Kim JH,Lee M.Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.J Hepatol2018;69:1066-73

[31] Chang MH,Chen CJ.Taiwan Hepatoma Study GroupLong-term effects of hepatitis B immunization of infants in preventing liver cancer.Gastroenterology2016;151:472-80.e1

[32] Koshiol J,Liu Z.Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virus- and hepatitis C virus-infected individuals.Aliment Pharmacol Ther2021;54:833-42

[33] Li X,Gao P.Fibrosis index based on 4 factors (FIB-4) predicts liver cirrhosis and hepatocellular carcinoma in chronic hepatitis C virus (HCV) patients.Med Sci Monit2019;25:7243-50 PMCID:PMC6784625

[34] Degasperi E,Iavarone M.Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection.Clin Gastroenterol Hepatol2019;17:1183-91.e7

[35] Ganne-Carrié N,Bourcier V.ANRS CO12 CirVir Study GroupNomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir).Hepatology2016;64:1136-47

[36] Lleo A,Aghemo A.Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals.Dig Liv Dis2019;51:310-7.

[37] Sangiovanni A,Gattai R.Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.J Hepatol2020;73:593-602

[38] Marrero JA,Sirlin CB.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases.Hepatology2018;68:723-50.

[39] Kanwal F,Asch SM,Cao Y.Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents.Gastroenterology2017;153:996-1005.e1

[40] Ioannou GN.HCC surveillance after SVR in patients with F3/F4 fibrosis.J Hepatol2021;74:458-65

[41] Beste LA,Berry K,Ioannou GN.Hepatitis C-related hepatocellular carcinoma incidence in the veterans health administration after introduction of direct-acting antivirals.JAMA2020;324:1003-5 PMCID:PMC7489813

[42] Audureau E,Layese R.ANRS CO12 CirVir groupPersonalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.J Hepatol2020;73:1434-45

[43] Younossi Z,Marietti M.Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol2018;15:11-20

[44] Estes C,Arias-Loste MT.Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.J Hepatol2018;69:896-904

[45] Ekstedt M,Nasr P.Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.Hepatology2015;61:1547-54

[46] Stine JG,Zimmet A.Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.Aliment Pharmacol Ther2018;48:696-703 PMCID:PMC7495494

[47] European Association for the Study of the LiverEASL clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[48] Orci LA,Caballol B.Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.Clin Gastroenterol Hepatol2022;20:283-92.e10

[49] Mittal S,Sada YH.Hepatocellular carcinoma in the absence of cirrhosis in United States Veterans is associated with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2016;14:124-31.e1 PMCID:PMC4690789

[50] Kanwal F,Mapakshi S.Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease.Gastroenterology2018;155:1828-37.e2 PMCID:PMC6279617

[51] Ioannou GN,Kerr KF.Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.J Hepatol2019;71:523-33 PMCID:PMC6702126

[52] Morgan TR,Jamal MM.Alcohol and hepatocellular carcinoma.Gastroenterology2004;127:S87-96

[53] Huang DQ,Ng CH.Hepatocellular carcinoma incidence in alcohol-associated cirrhosis: systematic review and meta-analysis.Clin Gastroenterol Hepatol2023;21:1169-77 PMCID:PMC10792532

[54] Turati F,Rota M.Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies.Ann Oncol2014;25:1526-35

[55] Lin CW,Mo LR.Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis.J Hepatol2013;58:730-5

[56] Innes HA,Barclay S.Hepatitis C Clinical Database Monitoring CommitteeQuantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness.Hepatology2013;57:451-60

[57] Kim JH,Park SW.Validation of modified fibrosis-4 index for predicting hepatocellular carcinoma in patients with compensated alcoholic liver cirrhosis.Medicine2018;97:e13438 PMCID:PMC6283079

[58] Tansel A,El-Serag HB.Incidence and determinants of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis.Clin Gastroenterol Hepatol2017;15:1207-17 PMCID:PMC5522646

[59] Colapietro F,Lytvyak E.Dutch AIH Study GroupInternational Autoimmune Hepatitis GroupIncidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis.J Hepatol2024;80:53-61

[60] Harada K,Ueno Y.Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan.Hepatology2013;57:1942-9

[61] Trivedi PJ,van Buuren HR.Global PBC Study GroupStratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study.Gut2016;65:321-9

[62] European Association for the Study of the LiverEASL clinical practice guidelines on haemochromatosis.J Hepatol2022;77:479-502

[63] Pfeiffenberger J,Gotthardt DN.Hepatobiliary malignancies in Wilson disease.Liver Int2015;35:1615-22